“E-nova premium” is a wireless device, based on Cradicell’s unique patentable technology which enables the acquisition of 12 lead ECG. Our technology monitors actual currents in the conventional monitoring points, delivering relatively accurate results.
Not every technology that reconstructs the heart’s dipole from reduced number of electrodes (i.e. the frank¹ lead system or the EASI² lead system) is accepted or recommended by major health organizations as equivalent to the conventional 12 leads ECG. That's because they may differ in their interval duration and amplitude from the corresponding standard ECGs. Furthermore, transformations of orthogonal data can be used to produce a synthesized 12-lead ECG, but the generalized transfer coefficients used in these estimations are subject to individual variability in torso shape and heterogeneities of impedance. Patient-specific transformations derived from comparison with a baseline 12-lead ECG can improve the accuracy of subsequent synthesized tracings, yet the electrical variables are not identical to the conventional monitoring. 

Our technology monitors more locations than the traditional 6 chest points. Although multi-lead systems did not prove to generate more accurate diagnosis in routine examinations of heart attacks, the recording of additional right-sided pre-cordial leads during acute inferior-wall left ventricular infarction is recommended. The use of additional posterior pre-cordial leads can be recommended in settings in which treatment will depend on documentation of ST elevation during infarction or other acute coronary syndrome.

          Conventional ECG                                 E-nova Premium

 Results of V3 lead of conventional ECG and the E-nova premium prototype

Milestones:
The development of our technology has begun in 2005. Not only experiments on humans have yielded high similarity to the conventional 12 lead ECG, but we also received encouraging responses from cardiologists.
The company expects to finalise its core-technology in Q3 of 2009, after which we will initiate multi-centre clinical trials.

¹ The Frank lead system obtaining reproducible orthogonal lead information using 7 electrodes 
² the EASI lead system containing a reduced 5-lead set to provide orthogonally oriented signals. In addition to orthogonal data, transfer coefficients have been developed for the EASI lead system that produce synthesized 12-lead ECGs.